AMBS Amarantus Biosciences, Inc. OTCQB

Amarantus BioSciences, Inc. (“Amarantus”) is focused on the discovery and development of therapeutic proteins with the potential to address critically important biological pathways involved in the treatment human diseases.

The Company’s lead program MANF is aimed at developing products to address the underlying Programmed Cell Death (Apoptosis) associated a wide range of devastating human disorders. With a global trend towards an prolonged life expectancy due to novel therapies and emerging countries gaining access to critical medical care, the development of Apoptosis-related treatments represents a significant market opportunity that addresses a critical unmet medical need: safely and effectively improving currently-approved patients treatments.

Amarantus’ business strategy, utilizing Amarantus’ seasoned Management Team, world-class Scientific Advisory Board and Board of Directors, is to employ our PhenoGuard Drug Discovery Engine to discover medically-relevant secreted human proteins, scientifically establish their therapeutic potential, develop pre-clinical and clinical programs to further their development, and advance them through successive de-risking milestones to maximize their commercial potential while making them attractive partnering targets for product development focused biotechnology, pharmaceutical, medical device and diagnostic companies

http://www.amarantus.com/

Shares Outstanding 81,016,330 a/o Nov 14, 2011
http://www.otcmarkets.com/stock/AMBS/news
http://www.otcmarkets.com/stock/AMBS/financials
Management Team

Gerald E. Commissiong

President & CEO
Mr. Commissiong was appointed President & CEO of Amarantus BioSciences in October 2011. In March 2011, Mr. Commissiong was

promoted to Chief Operating Officer of Amarantus, where his duties included strategic transactions, licensing, research

collaborations, mergers & acquisitions, fund raising and investor relations. From August 2009 until March 2011, he served as

Chief Business Officer where he was responsible for business development and corporate development. In 2008, Mr. Commissiong

co-founded Amarantus with Dr. John Commissiong PhD and served as its President & CEO until August 2009. In that timeframe,

Mr. Commissiong attracted seed capital, acquired the intellectual property rights to MANF and recruited scientific and

executive talent to Amarantus to allow for the further development of the technologies. Mr. Commissiong has served as a

Director of Amarantus since 2008. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the

Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering

with a focus Financial Decisions from Stanford University.

John W. Commissiong, PhD

Chief Scientific Officer
Dr. Commissiong has served as the Chief Scientific Officer and a Director of Amarantus since co-founding the company in 2009.

From 2000 through 2008 Dr. Commissiong served as the CSO of Neurotrophics Inc & Prescient Neuropharma Inc. Dr. Commissiong

has been focused on the discovery of novel neurotrophic factors for the treatment of neurodegenerative diseases as well as

understanding the fundamental underlying biology of protoplasmic type-1 astrocytes that secrete neurotrophic factors. He was

Chief of the Neural Transplantation Unit, NINDS-NIH, from 1989-94 where his research focused on identifying therapeutic

approaches to spinal cord injury. Dr. Commissiong was Head of the Neurotrophic Factors Group, NINDS-NIH, from 1994-97 where

he focused on developing technologies to systematically identify novel neurotrophic factors with applications for specific

Central Nervous System disorders. He co-founded Prescient Neuropharma in 1999, and discovered MANF in 2003. MANF is currently

in preclinical development for the treatment of Parkinson’s disease. The work pioneered by Dr. Commissiong has led to

significant advancements in the field of astrocyte-neuron biology. Dr. Commissiong believes that a fundamental understanding

of astrocyte-neuron interactions in the Central Nervous System will lead to a new generation of therapies to treat brain-

related disorders.
Dr. Commissiong did his Postdoctoral work in the Lab Preclin Pharmac, NIMH-NIH, concentrating on the application of

quadrupole mass spectrometry in the analysis of neurotransmitters. He holds a Ph.D. in Neurophysiology from the University of

Southampton, an M.Sc. in Biochemical Pharmacology from the University of Southampton, and a B.S. in Biology and Chemistry

from the University of the West Indies.

Marc E. Faerber

Controller / Chief Financial Officer Controller
Mr. Faerber has over thirty years of experience and over nineteen of those in life sciences. His experience has spanned

Fortune 500 companies to start-ups, and everything in between. During the past ten years Mr. Faerber has been providing

financial, business and advisory services to a broad base of start-up companies primarily in the fields of cardiology,

gastroenterology, orthopedics, diagnostics and biotechnology.
Mr. Faerber has extensive transactional experience, including considerable experience in establishing international

organizations throughout Europe and parts of Asia, international technology licensing and distribution transactions, mergers

and acquisitions, and numerous funding transactions, including an initial public offering as well as other international

business structural issues. During Mr. Faerber’s career he has held various positions in finance and corporate management

including CFO, CEO and Director. Mr. Faerber started his career working for KPMG, is a certified public accountant, and has a

Bachelor of Sciences in Business Administration from Providence College.

AMBS PR Dec/01/11 Amarantus BioSciences to Present at the National Investment Banking Association's (NIBA) 120th Investment Conference

SUNNYVALE, Calif., Dec 01, 2011 (BUSINESS WIRE) -- Amarantus BioSciences, Inc. (OTCBB:AMBS), a biotechnology company developing Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF), a first-in-class disease--modifying therapeutic protein, today announced that it has been selected to present at 120th National Investment Banking Association's Conference in Las Vegas, NV at Caesar's Palace on Thursday, December 1st at 10:10am Pacific.
NIBA is the only national not-for-profit trade association of regional and independent brokerages, investment banking firms, institutional investors and related capital market service providers. Since its inception, NIBA member firms have successfully completed over 1000 equity offerings totaling approximately $10 billion in new capital for America's finest emerging growth companies. The member firms of NIBA represent over 8000 registered representatives with an estimated $78 billion in assets under management, and are responsible for 90% of all Initial Public Offerings under $20 million.

NIBA conferences provide a venue for invited companies to share meaningful insight into their business operations, short and long-term growth strategies and industry vision, and give its members the opportunity to exchange ideas and information, evaluate presentations made by public and private companies seeking capital or exposure, collectively voice their positions on issues impacting the securities industry, and enhance their knowledge and expertise through ongoing education programs designed to enable them to remain competitive in today's financial market.

EVENT INFORMATION AT A GLANCE:





WHO: Gerald Commissiong, President and Chief Executive Officer
WHEN: November 30, 2011 - December 2, 2011
WHERE: Caesars Palace Las Vegas Hotel & Casino- 3570 Las Vegas Blvd South,
Las Vegas, NV

About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System (CNS) will be identified from the Company's inventory of PhenoGuard Cell Lines.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

AMBS News

NOKOMIS, Fla., May 04, 2012 (BUSINESS WIRE) -- Rainbow BioSciences, LLC, the biotech subsidiary of Rainbow Coral Corp. (RBCC), today announced the collaboration of its latest target, Amarantus BioSciences, Inc. /quotes/zigman/5369812/quotes/nls/ambs AMBS -12.50% , with Brewer Sports International (BSI) to increase awareness about new medical therapies in development to effectively treat traumatic brain injuries, commonly referred to as concussions, occurring primarily as a result of football and other contact sports.
The Coalition for Concussion Treatment campaign, known under its Twitter handle as #C4CT, has reached the critical milestone of 100 people signing a petition endorsing the movement and seeking to disseminate critical information about promising new therapies BSI will be identifying and raising awareness for over the next several months. Raising awareness of new advancement in developing treatments for TBI is critically important because it will allow the broader community to support drug developers' efforts.
Recent research on concussions suffered by athletes of all ages, including children, is rapidly changing the public's view of the impact these injuries have on players, including horrific side effects such as dementia and even suicide, as has been seen by the recent tragic deaths of certain current and former NFL and NHL players.
The newly formed Coalition for Concussion Treatment will focus on educating parents, players, fans and the sports community at large on the potential that new advances in developing new treatments for acute symptoms, as well as reducing the long-term negative impact of these devastating injuries have on the brain known as recovery of function. The sports community can have a meaningful positive influence on pushing new treatments in development forward.
AMBS is a biotech firm that has developed a therapeutic protein known as MANF to treat disorders associated with endoplasmic reticulum stress, including traumatic brain injury, Parkinson's disease, Alzheimer's disease and other afflictions. The firm is also working on a blood test designed to Parkinson's disease and has teamed up with Banyan Biomarkers, the leader in the development of in vitro diagnostics for concussions, on a new treatment for TBI. Amarantus and Banyan expect to release an update from their work to the public shortly.
RBCC signed a letter of intent with AMBS earlier this week.
As awareness and concern spreads regarding the devastating health issues that can accompany concussions, the market for the diagnostic and treatment options being developed by AMBS is growing by the day. The Coalition for Concussion Treatment stands poised to drive increases in demand for these products. It was created to begin a viral campaign through Twitter and other digital and social media outlets to help ignite awareness of the severity of concussions and enhance treatment efforts.
Despite the growing rate of incidence of traumatic brain injuries, very few treatments and no cures are yet available. RBCC and AMBS plan to help change that.
Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. /quotes/zigman/19815/quotes/nls/amgn AMGN -0.37% , Cell Therapeutics, Inc. /quotes/zigman/5103238/quotes/nls/ctic CTIC -1.85% , Abbott Laboratories /quotes/zigman/216393/quotes/nls/abt ABT +0.64% and Affymax, Inc/104161/quotes/nls. /quotes/zigman/affy AFFY -1.90% .
For more information on Rainbow BioSciences, please visit www.rainbowbiosciences.com/investors.html .

AMBS +.0025

http://www.amarantus.com

Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company is focused on developing unique products and proprietary technologies for the potential treatment and/or diagnosis of Parkinson's disease, Alzheimer's disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for neurological disorders where there is a significant unmet medical need.